December 19, 2024
In this webcast, Dr. Thomas Powles, Chair of Barts Cancer Centre (UK), joins Christopher Ung, our Chief Scientific Business Officer, for an in-depth conversation on the latest on Antibody Drug Conjugates (ADCs) and other innovative cancer therapies.
Watch the webcast
Key topics discussed in this webcast:
- The challenges of treating metastatic bladder cancer
- Targeting metastatic bladder cancer with Nectin-4 ADC
- New ways of thinking about biomarkers for ADCs
- How spatial biology could improve ADC assessment
- Bi-specifics and other innovative therapies for metastatic bladder cancer
- Being a physician and running clinical trials
Dr. Powles is a renowned expert in urology cancer and drug development, serving as the Chair of the Barts Cancer Centre at St. Bartholomew’s Hospital, Queen Mary University of London. He leads numerous clinical trials across all phases. Notably, his work in bladder and renal cancer has been pivotal in establishing new immunotherapy and antibody drug conjugate treatments as standards of care globally. Dr. Powles has been included in TIME’s list of the 100 most influential people in global health and in the Nature10 list in 2023.
Christopher Ung is CellCarta’s Chief Scientific Business Officer and has served in the companion diagnostics field since its inception. He is one of the original pioneers of the personalized medicine field. Mr. Ung currently leads the development and execution of CellCarta’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services.
You might also be interested by
Posters
Monitoring M-Protein Levels in Multiple Myeloma Using Microsampling Devices Coupled With Intact Mass High-Resolution Mass Spectrometry
November 19, 2024
More info